Science history: A tragic gene therapy death that stalled the field for a decade — Sept. 17, 1999
Rapid facts
Milestone: First of all reported Death due to gene therapy
Date: September 17, 1999
Or: University of Pennsylvania, in Philadelphia
WHOs: Jesse Gelsinger
Twenty-six years ago today, on September 17, a teenager who had received experimental gene therapy died. His death has led to necessary changes in the clinical trial process while stimulating skepticism that would end up stalling the field of gene therapy for years.
About 90% of babies With the most severe form of over -the -counter deficiency. But gelsinger – which had a softer and softer form of disease – had reached adulthood strictly adhering to a diet poor in protein and a diet of 50 pills per dayTo help reduce the amount of ammonia in your blood and compensate for its effects. Although Gelsinger is small for her age And experienced a dangerous ammonia crisis when he stopped taking his pills, he was otherwise in good health.
Gelsinger wanted to help newborns with the disease, so he signed up for a trial to test the safety of a gene therapy aimed at correcting the defective OTC gene. The treatment used a weakened form of an adenovirus, a type of cold virus, to deliver the corrected shape of the OTC gene in gelsinger cells.
Gelsinger flew to the University of Pennsylvania, where the test was organized and followed the treatment Infused in the artery fueling the liver on September 13, 1999. He had pseudo-Grippal symptoms that day, as planned. But the next day, he was designedHe developed a serious inflammatory reaction and A blood clotting disorderAnd his organs began to fail. He was withdrawn from life around 2:30 p.m. on September 17. Investigations revealed that his death was caused by a serious immune reaction to the virus used to issue treatment.
An investigation into the Food and Drug Administration (FDA) found many problems with the registration of Gelsinger at the trial, According to the New York Times. First, its liver function was too poor and the ammonia levels were too high when it started the trial. Second, the team did not reveal to patients that before the test, laboratory animals died of higher doses of therapy. In addition, other human participants had experienced serious side effects. Meanwhile, Dr. James Wilson, the principal researcher, held actions in Genovo, the company developing therapy, and stood to win millions If therapy has succeeded.
“We do not know what the impact of these differences are,” said the New York Times of the FDA, Dr. Kathryn Zoon, then director of the FDA Biology Center. “But they are important.”
The father of Gelsinger, Paul Gelsinger, launched an unjustified death costume against the parties involved in the trial; It was finally installed for an undisclosed sum.
The death of Gelsinger has led to several changes in the way clinical trials of gene therapy are executed and to stronger requirements for informed consent. All trials of ongoing gene therapy at the University of Pennsylvania have been interrupted. The FDA has also started to require greater monitoring of gene therapy trials.
Death threw a veil in the field and, as a public and private financing for the approach, gene therapy blocked. Finally, however, with progress in understanding the viral vectors used to provide gene therapy, and later, with the advent of the cutting and brownfield publishing tool CrisprThe field has rebounded.
Scientists have now used gene therapy to deal with many rare genetic disorders, especially Severe combined immuno-tail And several forms of blindness. THE First gene therapy based on Crisprwhich treats falciform anemia by deactivating a specific gene, was approved in January 2024. And in 2025, scientists announced that they had used a Personalized CRISPR treatment Designed for its particular genetic mutation to treat a baby with a rare and devastating genetic syndrome.
Right now, the The number of approved gene therapy products is still small. Many of these approved therapies use cells that are published in the laboratory, then are returned to the body to fight or treat cancer, rather than change the genes in the nucleus of a patient’s own cells.
But the estate has traveled a long way since the death of Gelsinger, and in 2021, scientists used gene therapy for Successfully treat the deficiency in OTC.
